FDA
-
-
-
-
-
-
-
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
-
-
-
-
-
-
-
U.S. District Court Upholds Validity of CINVANTI® Patents
-
-
-
-
-
-
-
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
-
-
-
-
-
-
-
Heron Therapeutics (HRTX) Announces Partnership with CrossLink Life Sciences to Expand Promotion for ZYNRELEF
-
-
-
-
-
-
-
Heron Therapeutics (HRTX) Announces New CEO and Board Chairman
-
-
-
-
-
-
-
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises
-
-
-
-
-
-
-
Heron Therapeutics Announces $76.5 Million Private Placement Financing
-
322,968 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

